Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Clin Cancer Res. 2010 Jul 13;16(14):3594–3606. doi: 10.1158/1078-0432.CCR-10-0192

Figure 5.

Figure 5

MUC-CD targeted 4H11-28z+ T cells traffic to peritoneal OV-CAR3(MUC-CD/GFP-FFLuc) tumors following systemic intravenous infusion resulting in efficient anti-tumor efficacy. (A) BLI of tumor progression of representative i.p. and i.v. 4H11-28z+ T cell treated mice with ultimately progressive disease following treatment compared to BLI of tumor progression in a representative control 19-28z+ T cell treated mouse. (B) Kaplan-Meier survival curve of SCID-Beige mice treated i.p. or i.v. with 4H11-28z+ T cells. Tumor eradication is enhanced after either ip or iv infusion of 4H11-28z+ T cells when compared to control treated mice. Both ip and iv 4H11-28z+ T cell treated mice exhibited statistically enhanced survival when compared to 19-28z+ T cell treated control cohorts while survival between the i.p. and i.v. treated 4H11-28z+ T cell cohorts was not statistically significant (p=0.22). (C) Systemically injected CFSE stained 4H11-28z+ T cells traffic to advanced i.p. OV-CAR(MUC-CD) tumors. Presence of i.v. injected CFSE labeled 19-28z+ control T cells (left panel) and 4H11-28z+ T cells (right panel) 1 day following infusion into SCID-Beige mice with OV-CAR(MUC-CD) tumors injected 7 days earlier as assessed by FACS analysis of single cell OV-CAR3(MUC-CD) tumor suspensions.